| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | 0.093 | 0.02 |
| mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | 0.088 | 0.02 |
| mRNA | JW-7-52-1 | GDSC1000 | pan-cancer | AAC | 0.13 | 0.02 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | 0.093 | 0.02 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | -0.08 | 0.02 |
| mRNA | QL-XI-92 | GDSC1000 | pan-cancer | AAC | 0.073 | 0.02 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | 0.079 | 0.02 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | 0.13 | 0.02 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.081 | 0.02 |
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | 0.13 | 0.02 |